Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FOUND: Conformis | Mind Blowing Facts

Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary

Akero Therapeutics (NASDAQ:AKRO) revealed topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with pre-cirrhotic nonalcoholic steatohepatitis (NASH), the study met its primary endpoint for both the 50mg and 28mg EFX dose groups. Akero Therapeutics shares…

Benzinga · Sep 13, 2022

Recap: Conformis Q1 Earnings

Conformis (NASDAQ:CFMS) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga · May 4, 2022

Earnings Preview: Conformis

Conformis (NASDAQ:CFMS) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Conformis will report an earnings per share (EPS) of $-0.07.

Benzinga · May 3, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Looking Into Conformis's Return On Capital Employed

Conformis (NASDAQ:CFMS) brought in sales totaling $15.42 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 23.15%, resulting in a loss of $15.98 million.

Benzinga · Mar 8, 2022

Conformis' Q4 Miss Street View As Earnings Impacted By Surge In COVID-19 Cases

Conformis Inc's (NASDAQ: CFMS)

Benzinga · Mar 3, 2022

A Preview Of Conformis's Earnings

Conformis (NASDAQ:CFMS) is set to give its latest quarterly earnings report on Wednesday, 2022-03-02. Here's what investors need to know before the announcement. Analysts estimate that Conformis will report an earnings per share (EPS) of $-0.07.

Benzinga · Mar 1, 2022

Coverage From

Benzinga

Organisations

US Food and Drug Administration

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.